14 studies on ARA-290 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Peptaris | 13 | 99.07% | View COA → |
| Protide Health | 4 | 99.58% | View COA → |
| Unknown vendor (review) | 4 | 99.57% | View COA → |
| VeriPure LLC | 4 | 99.48% | View COA → |
| Ion Peptide | 3 | 99.93% | View COA → |
| Qingdao Sigma Chemical | 3 | 99.76% | View COA → |
| Simple Peptide | 3 | 99.59% | View COA → |
| Alpha & Omega | 3 | 99.59% | View COA → |
Recent certificates: #38585 (99.67%) · #43985 (99.41%) · #48935 (99.15%) · #59064 (99.22%) · #36924 (99.92%) · #41226 (99.11%)
Manufacturers with published third-party certificates of analysis for ARA-290. Open a vendor to see every batch we've verified.
This comprehensive review consolidates critical knowledge on tissue-protective cytokines, particularly EPO, making it a valuable resource for researchers and clinicians. The detailed experimental protocols included in…
This research highlights the critical role of early monocyte modulation in influencing the trajectory of Alzheimer's disease (AD) pathology. The findings suggest that ARA 290 could represent a novel therapeutic strate…
This study provides compelling evidence that pHBSP can effectively reverse key pathological features of preeclampsia, particularly endothelial dysfunction and hypertension, in an animal model. The ability of pHBSP to …
This study's findings are significant because 99mTc-DOTA-ARA-290 offers a potentially superior method for non-invasive detection of cardiac ischemia, which could lead to earlier diagnosis and intervention. The high sp…
This research provides compelling evidence for ARA290's potential as a powerful cytoprotective agent, specifically in safeguarding healthy cells from the severe genotoxicity and oxidative stress induced by doxorubicin…
This study provides compelling mechanistic evidence that ARA290 can effectively protect against cisplatin-induced nephrotoxicity by simultaneously suppressing apoptosis and inflammation. The ability of ARA290 to targe…
This research introduces a potentially groundbreaking therapeutic strategy for combating age-related cardiovascular diseases. By utilizing a small erythropoietin-derived non-hematopoietic peptide, the study successful…
This research highlights ARA290 as a promising neuroprotective agent that directly safeguards brain tissue from the devastating effects of ischemic stroke. By targeting the β-common receptor, ARA290 offers a novel mec…
This research highlights a critical, selective impact of immunometabolic dysregulation on executive cognitive function, a domain essential for planning, problem-solving, and decision-making. The findings suggest that …
The exploration of ARA 290, a non-hematopoietic erythropoietin analogue, holds significant promise as it targets a novel mechanism for glucose regulation, potentially offering a new therapeutic avenue beyond existing …
If the study's hypothesis of a positive shift in emotional processing was confirmed, it would represent a significant step forward in neuroscience and psychopharmacology. This could establish ARA290 as a promising can…
Free, no account — handy when you're working with ARA-290.